化疗相关性恶心呕吐的回顾性研究

临床肿瘤学杂志 ›› 2018, Vol. 23 ›› Issue (5): 440-443.

化疗相关性恶心呕吐的回顾性研究

200433 上海海军军医大学附属长海医院肿瘤科

收稿日期:2018-01-19 修回日期:2018-03-23 出版日期:2018-05-31 发布日期:2018-06-07

Adherence to NCCN antiemesis guideline for chemotherapy induced nausea and vomiting： A retrospective study in changhai hospital

Department of Oncology， Changhai Hospital， Shanghai 200433，China

Received:2018-01-19 Revised:2018-03-23 Online:2018-05-31 Published:2018-06-07

摘要/Abstract

摘要： 目的调查肿瘤患者在化疗期间止吐药物的应用情况，为合理用药提供参考。方法回顾性分析长海医院肿瘤科2016年6月至2017年5月期间收治533例肿瘤患者的病历资料，收集患者年龄、原发肿瘤诊断、化疗方案及其致吐性、指南依从性等。参考NCCN指南分别对接受单日化疗方案和多日化疗方案的患者资料进行描述性统计分析。结果 533例接受化疗的患者中5-HT3受体拮抗剂预防性止吐治疗比例达100％。其中多日化疗的高度致吐风险方案的指南符合率高于单日化疗（22.29％ vs. 15.79％）。结论肿瘤患者预防性应用止吐药物以5-HT3受体拮抗剂联合激素为主，止吐药物使用的指南符合率低与阿瑞匹坦的可及性有关。

关键词: 化疗所致恶心呕吐（CINV）, 化学治疗, 5-HT3受体拮抗剂, NK-1受体拮抗剂

Abstract: Objective To investigate the application of antiemetic drugs in cancer patients during chemotherapy， so as to provide reference for rational drug use. Methods Clinical data of 533 tumor patients receiving chemotherapy in changhai hospital from June 2016 to May 2017 were retrospectively analyzed， and variables including age， primary tumor diagnosis， chemotherapy regimen and its emetogenic risk， adherence to guidline were collected. In this study， a descriptive statistical analysis was applied on the data of patients receiving single day or multiday chemotherapy regimen， according to NCCN antiemesis guideline. Results In 533 patients receiving chemotherapy， the proportion of 5-HT3 antagonist preventive antiemetic therapy was 100％. Among them， the guidelines for high risk of vomiting were in accordance with the rate of chemotherapy. The daily chemotherapy was higher than that of the single day chemotherapy， which was 22.29％ and 15.79％ respectively. Conclusion The prophylactic use of antiemetic drugs in cancer patients is based on 5-HT3 receptor antagonist combined with hormone， and the low compliance rate of antiemetic drug use is associated with the accessibility of aprepitant.

Key words: Chemotherapy induced nausea and vomiting（CINV）, Chemotherapy, 5-HT3 receptor antagonist, NK-1 receptor antagonist

中图分类号:

R730

许晶, 李洁, 张美静, 陈龙佩, 龙菲, 王薇, 湛先保. 化疗相关性恶心呕吐的回顾性研究[J]. 临床肿瘤学杂志, 2018, 23(5): 440-443.

XU Jing, LI Jie, ZHANG Meijing, CHEN Longpei, LONG fei, WANG Wei, ZHAN Xianbao.. Adherence to NCCN antiemesis guideline for chemotherapy induced nausea and vomiting： A retrospective study in changhai hospital[J]. Chinese Clinical Oncology, 2018, 23(5): 440-443.

参考文献

Metrics

Viewed

Full text

Abstract

Cited

Shared

Discussed

本文评价

推荐阅读 10

[1]	刘锦；李贵新；马传香. 恶性黑色素瘤腹腔转移１例[J]. 临床肿瘤学杂志, 2009, 14(1): 96 .
[2]	石　玮¹，华海清²，王兴华¹. 放疗对肠屏障功能的影响及研究进展[J]. 临床肿瘤学杂志, 2009, 14(1): 89 .
[3]	王杰军，李　睿. ＮＣＣＮ成人癌痛临床实践指南解读[J]. 临床肿瘤学杂志, 2009, 14(1): 80 .
[4]	崔传亮，迟志宏，袁香庆，斯　璐，盛锡楠，郭　军. 重组人血管内皮抑制素联合化疗一线治疗晚期黑色素瘤的Ⅱ期临床研究[J]. 临床肿瘤学杂志, 2009, 14(1): 74 .
[5]	高亚杰¹，关小倩¹，杨海林¹，张　阳²，欧阳学农³，杨建伟⁴，陈　焰⁵,徐建明⁶，赵宣良⁷，王宝成⁸，刘文超⁹，张贺龙¹⁰，南克俊¹¹，王湘辉¹² . 注射用左亚叶酸钙联合治疗晚期胃癌和结直肠癌的Ⅱ期临床研究[J]. 临床肿瘤学杂志, 2009, 14(1): 47 .
[6]	白秀丽¹，马振刚¹，李际君². 紫杉醇联合卡培他滨治疗进展期胃癌的临床观察[J]. 临床肿瘤学杂志, 2009, 14(1): 68 .
[7]	徐卫国¹，杨小青²，郝世柱¹，宋纪宁¹，张鹏东¹，胡潺潺¹，王文雅¹. 大肠癌组织中Ｎｅｕｒｏｐｉｌｉｎ-１的表达及其与肿瘤血管生成的相关性研究[J]. 临床肿瘤学杂志, 2009, 14(1): 29 .
[8]	许景艳¹，欧阳建^１，章宜芬²，周荣富¹，陈　兵¹，张启国¹，杨永公¹，邵小雁¹，徐　勇¹，关朝阳¹. 原发性肋骨血管肉瘤的诊治探讨[J]. 临床肿瘤学杂志, 2009, 14(1): 70 .
[9]	徐晓明¹，唐金海¹，刘万花²，郑凯尔²，秦建伟¹，赵祥生¹，张　彤³. 触诊阴性乳腺癌的定位方法与同期手术治疗[J]. 临床肿瘤学杂志, 2009, 14(1): 43 .
[10]	张艳玲，邹　岚，肖　红，黄海辉，谭崇富，阮志华，王　希，梁后杰，庞学利. 影像引导调强放射治疗鼻咽癌[J]. 临床肿瘤学杂志, 2009, 14(1): 51 .